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Background: Transforming growth factor β (TGF-β) signaling functions as a suppressor or a promoter in tumor
development, depending on the tumor stage and type. However, the role of TGF-β signaling in nonfunctioning
pituitary adenomas (NFPAs) has not been explored.
Methods: TGF-β1, Smad2, phospho-Smad2 (p-Smad2), Smad3, phospho-Smad3 (p-Smad3), Smad4, and Smad7
were detected in 5 cases of normal anterior pituitaries, 29 cases of invasive NFPAs, and 21 cases of noninvasive
NFPAs by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blot,
and immunohistochemical analysis.
Results: The Smad3 and p-Smad3 protein levels gradually decreased from normal anterior pituitaries, noninvasive
NFPAs, to invasive NFPAs. However, there were no significant differences in Smad2 (P = 0.122) and p-Smad2 protein
levels (P = 0.101) or Smad2 mRNA level (P = 0.409). In addition, the TGF-β1 mRNA level gradually decreased while
the Smad7 mRNA level gradually increased from normal anterior pituitaries, noninvasive NFPAs, to invasive NFPAs.
Furthermore, proliferating cell nuclear antigen (PCNA) mRNA level was markedly increased in invasive NFPAs compared
to noninvasive ones (P < 0.01), and its level was negatively correlated with Smad3 mRNA level (P < 0.01).
Conclusion: The activity of TGF-β signaling may be restrained in NFPAs and is correlated with the development and
invasion of NFPAs.
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Pituitary adenomas (PAs) account for up to 15% of intra-
cranial tumors and have a prevalence of 80–90/100,000
people [1,2]. Only approximately 0.2% of PAs with sub-
arachnoid, brain, or systemic metastasis are considered
to be malignant [3]. However, many PAs are capable of
aggressive growth and invade surrounding structures
such as the sphenoidal sinus, cavernous sinus, and third
ventricle, and are described as invasive PAs. Curative
radical surgery remains difficult for invasive PAs, which
tend to recur quickly and even have a fatal outcome [4].* Correspondence: zyz2004520@yeah.net
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unless otherwise stated.Nonfunctioning pituitary adenomas (NFPAs) consist of
approximately 30% of all pituitary tumors, reflecting a very
heterogeneous group [5]. As hormonal inactivity leads to
delayed diagnosis compared with functioning PAs, NFPAs
sometimes present with invasive macroadenomas that
cause severe neurological symptoms [6]. There is no effect-
ive drug for most cases of NFPAs, while radiotherapy has
potential side effects including hypopituitarism, neurocog-
nitive dysfunction, and cerebrovascular disease [6]. There-
fore, NFPA therapy remains a challenge for clinicians.
PAs are monoclonal in nature, suggesting that they arise
from a primary abnormal pituitary cell that possesses a
unique proliferation advantage [7]. Subsequently, additional
tumor-promoting factors may confer increased proliferativel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of patients
Invasive NFPAs Noninvasive NFPAs
Demographics
Number 29 21
Age (years) 51.9 ± 11.0 (26–68) 49.6 ± 9.9 (29–71)
Male/Female 13 (44.8%)/16 (55.2%) 11 (52.4%)/10 (47.6%)
Symptom
Headache 20 (69.0%) 10 (47.6%)
Visual deficit 13 (44.8%) 6 (28.6%)
Hypopituitarism 14 (48.3%) 2 ( 9.5%)
None 3 (10.3%) 12 (57.1%)
Classification
NF+ 4 (13.8%) 3 (14.3%)
NF- 25 (86.2%) 18 (85.7%)
Tumor size (cm)
<3 2 ( 6.9%) 18 (85.8%)
≥3 27 (93.1%) 3 (14.2%)
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mechanisms of aggressive biological behavior of some
PAs have not been fully understood [8,9].
Transforming growth factor β (TGF-β) signaling func-
tions as a suppressor or a promoter in tumor develop-
ment, depending on the tumor stage and type [10,11].
TGF-β signaling is initiated by the binding of ligands
(TGF-β1, TGF-β2, and TGF-β3) to type II TGF-β recep-
tors (TGF-β RII), followed by recruitment of the type I
TGF-β receptor (TGF-β RI) to form the complex. Next,
TGF-β RII phosphorylates TGF-β RI to activate it. Acti-
vated TGF-β RI propagates signaling by phosphorylating
Smad2 and Smad3, which then form a heteromeric
complex with Smad4 and translocate into the nucleus to
regulate gene expression. Smad7 inhibits TGF-β mediated
phosphorylation of Smad2 and Smad3, thereby sup-
pressing downstream TGF-β signaling [12-14].
The clinical significance of TGF-β ligands and down-
stream signaling mediators has been studied in many
types of tumors, and the results are discordant [15-18].
Until now, the role of TGF-β signaling in the develop-
ment and invasion of NFPAs has not been explored. In
order to investigate the role of the TGF-β signaling path-
way in tumor development, combining several biomarkers
of the TGF-β pathway may be superior to the analysis of a
single component of the pathway [18]. Accordingly, in this
study, we examined the expression of TGF-β1, Smad2,
phospho-Smad2 (p-Smad2), Smad3, phospho-Smad3
(p-Smad3), Smad4, and Smad7 in normal anterior pi-
tuitaries, invasive NFPAs, and noninvasive NFPAs and
evaluated whether they were correlated with tumor devel-
opment and invasion. Additionally, proliferating cell




NFPAs were obtained from 50 patients (23 men and 27
women; 50.9 ± 10.5 years; range, 26–71 years) who under-
went endoscopic transsphenoidal surgery between March
2010 and December 2012 at Beijing Tiantan Hospital. Pa-
tients who had received previous radiation therapy or had
recurrence were not included in this study. The diagnosis
of NFPA was confirmed according to clinical manifest-
ation, hormonal and magnetic resonance imaging (MRI)
information, as well as histopathological analysis and im-
munohistochemical staining for all anterior pituitary hor-
mones. Forty-three NFPAs were negative for hormone
expression, and seven NFPAs were positive for luteinizing
hormone (LH) and/or follicle-stimulating hormone (FSH).
NFPAs that were stained positive for hormone expres-
sion were termed NF+PAs, whereas those negative for
hormone expression were considered NF−PAs. In addition,
five normal human anterior pituitaries were obtainedfrom a donation program. All of the donors died of
non-neurological and nonendocrine diseases. The donors
consisted of 3 men and 2 women (35.6 ± 9.8 years; range,
32–54 years). Invasive PAs were defined as grade IV based
on Hardy-Wilson classification and/or grade III and IV
based on Knosp classification [19,20]. There were 29 inva-
sive NFPAs and 21 noninvasive NFPAs. The study proto-
col was approved by the Ethics Committee of Beijing
Tiantan Hospital, and informed consent was obtained
from all patients. The patient characteristics are summa-
rized in Table 1.
Real-time quantitative reverse transcription polymerase
chain reaction (qRT-PCR)
NFPAs and normal human anterior pituitaries were
stored in liquid nitrogen immediately after harvesting.
Total RNA was extracted from the frozen tumor samples
and normal anterior pituitaries using Trizol (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. The purity and concentration of RNA were
determined by a NanoDrop 1000 instrument (Thermo
Scientific, Wilmington, DE). The cDNA was synthesized
from total RNA (5 μg) using a first-strand cDNA synthesis
kit (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. qRT-PCR was performed
on an ABI 7500 Fast system (Applied Biosystems, Foster
City, CA, USA) using the Platinum SYBR Green qPCR
SuperMix-UDG kit (Invitrogen, Carlsbad, CA, USA) ac-
cording to the manufacturer’s instructions. The amplifica-
tion conditions were 50°C for 2 min, 95°C for 2 min, then
40 cycles at 95°C for 15 s and 60°C for 30 s. GAPDH was
used as an internal control. Relative mRNA levels were cal-
culated based on the CT values, corrected for GAPDH
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gene of interest – CT GAPDH) [21]. PCR specificity was
determined by dissociation curve analysis. All qRT-PCRs
were performed in triplicate. The primers used for RT-
PCR are listed in Table 2.
Western blot analysis
Total protein was extracted from NFPAs or normal pitu-
itaries using lysis buffer (Applygen, Beijing, China) fol-
lowing the manufacturer’s instructions. The protein
concentration was measured using the bicinchoninic
acid method. Protein samples (30 μg) were separated by
electrophoresis using 10% sodium dodecyl sulfate poly-
acrylamide gels, and then transferred to polyvinylidene
difluoride membranes. The membranes were blocked
with 5% bovine serum albumin in Tris-buffered saline
containing 0.1% Tween 20, and incubated with rabbit
antibodies against human Smad2 (1:1000; Cell Signaling
Technology, Boston, MA, USA), p-Smad2 (Ser465/467)
(1:1000; Cell Signaling Technology, Boston, MA, USA),
Smad3 (1:1000; Cell Signaling Technology, Boston, MA,
USA), p-Smad3 (Ser423/425) (1:1000; Cell Signaling
Technology, Boston, MA, USA), and GAPDH (1:5000;
Sigma-Aldrich, St. Louis, MO, USA). Subsequently, the
membranes were incubated with the secondary antibody
anti-rabbit IgG (1:4000; Jackson ImmunoResearch Labora-
tories, West Grove, PA, USA). Finally, the membranes
were developed using an ultrasensitive chemilumines-
cence protein dye detection system (ECL Plus; Amersham
Pharmacia Biotech, Piscataway, NJ, USA) and exposed to
X-ray films (Kodak, Rochester, NY, USA). The bands were
subjected to grayscale scanning and semi-quantitative
analysis using Quantity One software (Bio-Rad, Hercules,
CA, USA).
Immunohistochemistry
The tissues were fixed in 10% buffered formalin and em-
bedded in paraffin. Paraffin-embedded tissues were cut
into 5-μm serial sections, then transferred onto adhesive
slides, and dried at 65°C for 30 min. The sections were
deparaffinized with xylene and rehydrated through graded
alcohol soluntions. Endogenous peroxidase activity wasTable 2 Primers used in this study







GAPDH GAAGGTCGGAGTCAACGGATT CGCTCCTGGAAGATGGTGATblocked with 3% hydrogen peroxide solution for 30 min,
and antigen retrieval was performed at 100°C for 20 min in
citrate buffer (10 mM, pH 6.0). After washing three times
with phosphate-buffered saline (PBS) for 5 min each, the
sections were incubated with 10% normal goat serum to
block nonspecific binding. Then, the sections were incu-
bated with Smad3 (1:100; Abcam, Cambridge, MA, USA)
or p-Smad3 (Ser423/425) (1:100; Abcam, Cambridge,
MA, USA) antibody at 4°C overnight followed by
immunodetection using the two-step polymer detec-
tion system (Polink-2 plus Kit; GBI Labs, Manchester,
England) and visualized with 3,3′-diaminobenzidine.
The slides were counterstained with Mayer’s hematoxylin,
dehydrated in graded alcohol, and mounted with a neutral
resin. For a negative control, the primary antibody was re-
placed with PBS.
All sections were examined and scored by both two
pathologists without knowledge of the patient’s clinical
record. Five fields at 400× magnification were randomly
selected. Staining scores for Smad3 and p-Smad3 were
determined by a semi-quantitative system, using the per-
centage of positive cells and staining intensity from 1 to
3 (1, weak; 2, moderate; and 3, strong), and the immuno-
staining results were classified according to the scores as
negative (0–30), weakly positive (31–150), or strongly
positive (150–300) [22].
Statistical analysis
Statistical analysis was performed with SPSS v16.0 soft-
ware (IBM Corporation, Armonk, NY, USA). The data
were expressed as mean ± standard deviation. Differ-
ences between groups were determined by one-way ana-
lysis of variance and the two independent samples t-test
or the Mann–Whitney U test. The correlation analysis
was assessed by Spearman’s rank correlation. P < 0.05
was defined as statistically significant.
Results
Comparison of Smad3 and p-Smad3 levels in invasive
NFPAs and noninvasive NFPAs
Western blot analysis demonstrated that the Smad3 pro-
tein level was significantly less in invasive NFPAs (P < 0.01)
and noninvasive NFPAs (P < 0.01) compared to normal
anterior pituitaries (Figure 1A and B). In addition,
the Smad3 protein level was significantly less in inva-
sive NFPAs compared to noninvasive NFPAs (P < 0.05)
(Figure 1A and B).
Next, we detected Smad3 mRNA expression by qRT-
PCR. The Smad3 mRNA level was significantly less in in-
vasive NFPAs (P < 0.01) and noninvasive NFPAs (P < 0.05)
compared to normal anterior pituitaries (Figure 1D).
Moreover, Smad3 mRNA level was significantly less in in-
vasive NFPAs compared to noninvasive NFPAs (P < 0.01)
(Figure 1D). The correlation coefficient between Smad3
Figure 1 Western blot and qRT-PCR analyses of Smad3 and p-Smad3. (A, B and C) Western blot and densitometric analyses of Smad3 and
p-Smad3. (D) qRT-PCR analysis of Smad3. *, P < 0.05; **, P < 0.01.
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strong correlation between Smad3 mRNA and protein
levels.
By immunohistochemical analysis, Smad3 and p-Smad3
protein were detected in nearly all anterior pituitary cells.
The Smad3 level was significantly less in invasive NFPAs
compared to noninvasive NFPAs (P < 0.01) (Figure 2A, B
and E). Smad3-positive staining was observed predomin-
antly at the cell membrane and/or in the cytoplasm, as
well as in the nucleus.
For determination of the activated Smad3 (p-Smad3)
protein level, western blot analysis showed that the
p-Smad3 protein level was significantly less in inva-
sive NFPAs (P < 0.01) and noninvasive NFPAs (P < 0.01)
compared to normal anterior pituitaries (Figure 1A and
C). In addition, the p-Smad3 protein level was significantly
less in invasive NFPAs compared to noninvasive NFPAs
(P < 0.01) (Figure1A and C). Immunohistochemical ana-
lysis confirmed that the p-Smad3 level was significantly
less in invasive NFPAs compared to noninvasive NFPAs
(P < 0.01) (Figure 2C, D, and F). p-Smad3-positive stainingwas observed predominantly in the nucleus, as well as at
the membrane and/or in the cytoplasm.
Comparison of Smad2 and p-Smad2 levels in invasive
NFPAs and noninvasive NFPAs
By Western blot and qRT-PCR analyses, we found no
significant difference in Smad2 (P = 0.122) or p-Smad2
protein levels (P = 0.101) (Figure 3) or the Smad2 mRNA
level in normal pituitary tissues, invasive NFPAs, and
noninvasive NFPAs (P = 0.409) (Figure 3).
Comparison of TGF-β1, Smad7, and Smad4 levels in inva-
sive NFPAs and noninvasive NFPAs
qRT-PCR analysis showed that the TGF-β1 mRNA level
was significantly less in invasive NFPAs (P < 0.01) and
noninvasive NFPAs (P < 0.01) compared to normal anter-
ior pituitaries (Figure 4A). In addition, the TGF-β1 mRNA
level was significantly less in invasive NFPAs compared to
noninvasive NFPAs (P < 0.01) (Figure 4A).
On the contrary, the Smad7 mRNA level was signifi-
cantly greater in invasive NFPAs (P < 0.01) and noninvasive
Figure 2 Immunohistochemical analysis of Smad3 and p-Smad3. (A) Low Smad3 expression in invasive NFPA (case 1). (B) High Smad3
expression in noninvasive NFPA (case 2). (C) Low p-Smad3 expression in invasive NFPA (case 1). (D) High p-Smad3 expression in noninvasive
NFPA (case 2). (E and F) The staining scores of Smad3 and p-Smad3. Magnification: 400×. **, P < 0.01.
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(Figure 4B). Moreover, the Smad7 mRNA level was
greater in invasive NFPAs than in noninvasive ones
(P < 0.01) (Figure 4B).
The Smad4 mRNA level was greater in noninvasive
NFPAs than in normal anterior pituitaries (P < 0.05)
(Figure 4C). However, there was no difference in the ex-
pression of Smad4 mRNA between invasive and nonin-
vasive NFPAs (P = 0.076) (Figure 4C). In addition, there
was no significant difference in the Smad4 mRNA level
between invasive NFPAs and normal anterior pituitaries
(P = 0.897) (Figure 4C).
As an indicator for the proliferation activity of tumor
cells, PCNA was used to evaluate tumor growth. qRT-PCR
analysis showed that the PCNA mRNA level was markedly
greater in invasive NFPAs compared to noninvasive ones
(P < 0.01) (Figure 4D). By Spearman’s rank correlation ana-
lysis, the PCNA mRNA level showed a significant correl-
ation with the Smad3 mRNA level (P < 0.01, r = −0.697).
However, the PCNA mRNA level was not significantly
correlated with the level of Smad2 (P = 0.232), Smad4
(P = 0.263), Smad7 (P = 0.242), or TGF-β1 (P = 0.171).
Discussion
The TGF-β signaling pathway is involved in a diverse set of
cellular processes, such as cell proliferation, differentiation,migration, apoptosis, and biological processes includ-
ing embryonic development, immunity regulation, and
tissue homeostasis [23-25]. The role of TGF-β signaling in
tumorigenesis is complex. In normal epithelial cells, TGF-β
acts as a potent tumor suppressor and prevents incipient
tumors from progression to malignancy [11]. However, due
to subsequent inactivation of TGF-β signaling or key target
genes, malignant cells will lose TGF-β tumor-suppressive
responses. In addition, pathological forms of TGF-β sig-
naling can promote tumor growth and invasion, the
evasion of immune surveillance, and tumor cell dis-
semination and metastasis [11].
Several studies have shown the tumor suppressor role
of Smad3, whose deficiency contributes to tumor forma-
tion and development [26,27]. Consistently, we found
that a low Smad3 or p-Smad3 protein level and a low
Smad3 mRNA level were closely associated with NFPA
development and invasion. Smad7 is an inhibitory Smad,
which can suppress TGF-β-mediated phosphorylation
of Smad2 and Smad3 as well as prevent their inter-
action with Smad4 and subsequent nuclear transloca-
tion. Kleeff et al. have demonstrated that Smad7 enhances
tumorigenicity in pancreatic cancer [28]. Moreover, Halder
et al. have reported that Smad7 induces hepatic metas-
tasis in colorectal cancer [29]. In this study, we found that
the expression of Smad7 mRNA increased gradually from
Figure 3 Western blot and qRT-PCR analyses of Smad2 and p-Smad2. (A, B and C) Western blot and densitometric analyses of Smad2 and
p-Smad2. (D) qRT-PCR analysis of Smad2.
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sive NFPAs, implying that the upregulation of Smad7 con-
tributes to NFPA development. These data suggest that
the balance between Smad3 and Smad7 may affect the de-
velopment and invasion of NFPAs.
Smad4 was originally identified as a tumor suppressor
gene in pancreatic carcinomas [30]. Subsequently, many
studies have shown that Smad4 is underexpressed in
various human tumors, including stomach cancer, squa-
mous cell carcinoma of the esophagus, and breast cancer,
and Smad4 has been proposed as a prognostic marker
for tumor formation and progression [18,31,32]. Sur-
prisingly, in the present study, we found that the Smad4
mRNA level was greater in noninvasive NFPAs than in
normal anterior pituitaries. In addition, the difference in
the Smad4 mRNA level between invasive NFPAs and nor-
mal anterior pituitaries was not significant. Moreover,
there was no significant difference in the Smad4 mRNA
level between invasive and noninvasive NFPAs. Theseresults suggest that Smad4 may not act as a tumor sup-
pressor in NFPAs, but further studies are needed to con-
firm our speculation.
Since TGF-β1 is upregulated to a greater extent than
either TGF-β2 or TGF-β3 in cancer, TGF-β1 has been
the focus for cancer researchers [33]. Interestingly, we
found that the TGF-β1 mRNA level gradually decreased
from normal anterior pituitaries, noninvasive NFPAs, to
invasive NFPAs. These data indicate that TGF-β1 may be
a suppressor of NFPA development and invasion. It has
been shown that the thrombospondin-1 analogs ABT-510
and ABT-898 increased the activation of TGF-β1 in the
pituitary, possibly contributing to the inhibition of prolac-
tinoma growth [34].
Additionally, we evaluated the expression of PCNA
mRNA and found that increased PCNA mRNA expres-
sion was associated with NFPA invasiveness. PCNA is a
nuclear protein that has been identified as the auxiliary
protein of deoxyribonucleic acid polymerase delta, and
Figure 4 qRT-PCR analysis of TGF-β1, Smad7, Smad4 and PCNA. (A) The mRNA expression of TGF-β1. (B) The mRNA expression of Smad7.
(C) The mRNA expression of Smad4. (D) The mRNA expression of PCNA. *, P < 0.05; **, P < 0.01.
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[35]. A previous study has reported that the PCNA level
was greater in macroadenomas than in microadenomas
and that a higher PCNA index was correlated with a
shorter disease-free interval [36]. Furthermore, we found
that the PCNA level was negatively correlated to the
Smad3 level, suggesting that downregulation of Smad3
may contribute to the inactivation of TGF-β signaling
and the promotion of tumor growth.
To the best of our knowledge, this is the first study to
systematically investigate the differential expression of
TGF-β signaling pathway components in the normal
pituitary, invasive NFPAs, and noninvasive NFPAs.
We hypothesized that the activity of TGF-β signaling
is restrained and that the role of TGF-β in tumor sup-
pression is impaired in NFPAs. Thus, NFPAs have not
circumvented the suppressive effects of the TGF-β signal-
ing pathway. Consequently, recovering the capability of
TGF-β signaling to suppress tumor development is a
promising therapeutic strategy for NFPAs, especially
for invasive NFPAs.
Furthermore, our data suggest that Smad3 and p-Smad3
may be used as significant biomarkers to identify in-
vasive NFPAs in clinical practice. So far, only a few bio-
markers have been proposed to discern invasive NFPAs.By immunohistochemical and western blot analyses, we
found that Smad3 and p-Smad3 levels were negatively
correlated with tumor invasion. Consequently, Smad3 and
p-Smad3 may be useful biomarkers for the diagnosis of in-
vasive NFPAs.
However, there were several limitations of our study.
Firstly, due to the small sample size in our study, there
may be some selection bias, and we think that it is ne-
cessary to confirm our conclusion in further study with a
large sample size. In addition, active TGF-β1, which is
relative to the total [37], is very low. It was not taken into
account because tumor samples we obtained were few
and they were not uniformly available across studies.
In summary, this study demonstrated that a low Smad3
or p-Smad3 protein level was closely associated with
NFPA development and invasion. Moreover, the low ex-
pression of Smad3 and TGF-β1 mRNA and the high ex-
pression of Smad7 mRNA were associated with NFPA
development and invasion. These data suggest that the
TGF-β signaling pathway plays an important role in the
progression and invasion of NFPAs and promises to be a
new target for the diagnosis and treatment of NFPAs.
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